Johnson & Johnson announced the submission of regulatory applications to the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) seeking approval of a new indication for Darzalex ...
Syncona Ltd (SYNC.L) said that its portfolio company Autolus Therapeutics announced that the U.S. Food and Drug Administration has ...
Neurizon Therapeutics Limited (ASX: NUZ & NUZOA) ("Neurizon" or "the Company"), a clinical-stage biotech company advancing ...
A fatal, highly hereditary illness with no disease-modifying treatments, Huntington’s is long overdue for a therapeutic win.
The past four years have brought disappointment for the Huntington’s community, but optimism is growing as companies ...
Neurizon has been buoyed by the receipt of a positive opinion from the European Medicines Agency in relation to its ...
HotCopper.com on MSN10h
Neurizon's fast-track application for flagship drug in Europe received 'positively'While the final decision is set for next month, biotech player Neurizon’s (ASX:NUZ) hopes have been lifted with a view ...
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Raritan: Johnson & Johnson has announced the submission of regulatory applications to the U.S. Food and Drug Administration ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback